Saturday 17 October 2026
Export OMDA’s income statement to Excel — free account
Omada Health, Inc.
OMDA Healthcare Health Information Services
Omada Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $260.2 million, up 53.2% from fiscal 2024. In the quarter to June 2026, revenue grew 43.1%, EPS grew 137.5% and free cash flow grew 45.7%, each against the same quarter a year earlier.
17.63
1.04
−5.57%
Follow OMDA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+6 more quarters Free account |
0.00 | 0.00 | 0.00 | 313.57 |
P/S ratio |
5.55 | 2.22 | 2.61 | 4.23 | |
P/FCF ratio |
0.00 | 46.55 | 45.17 | 76.47 | |
P/Operating CF |
125.81 | 27.04 | (62.59) | 326.95 | |
P/B ratio |
5.87 | 2.52 | 3.16 | 5.18 | |
Price to Tangible BV |
6.33 | 2.70 | 3.38 | 5.51 | |
EV/Sales |
4.81 | 1.48 | 1.97 | 3.61 | |
EV/EBITDA |
0.00 | 0.00 | 533.27 | 121.98 | |
EV/Operating CF |
(115.06) | 21.15 | 24.80 | 47.22 | |
EV/FCF |
(73.41) | 31.09 | 34.09 | 65.28 | |
Quick Ratio |
3.42 | 3.39 | 3.67 | 3.69 | |
Current Ratio |
3.64 | 3.60 | 3.92 | 3.91 | |
Net Debt/EBITDA |
923.85 | (39.65) | 91.48 | (36.36) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.60 | 1.70 | 1.87 | 0.98 | |
Operating CF/Net income |
(3.19) | 4.14 | 3.98 | 0.76 | |
Capex/Depreciation |
(0.86) | (0.58) | (0.63) | (0.65) | |
Interest Coverage |
(7.12) | 252.38 | (265.61) | 253.50 | |
Research and Development Expense of Revenue |
15.14% | 15.23% | 16.27% | 16.65% | |
Selling, General and Administrative Expense of Revenue |
54.80% | 51.19% | 52.25% | 51.93% | |
Intangible Assets out of Total Assets |
0.06 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
5.20% | 4.94% | 5.39% | 6.41% | |
Graham Net Nets |
0.14 | 0.34 | 0.27 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 2.58 | |
Earnings Yield |
(11.90%) | (8.60%) | (2.07%) | 0.32% | |
Free Cash Flow Yield |
(1.18%) | 2.15% | 2.21% | 1.31% | |
Revenue per Share |
1.18 | 2.07 | 1.32 | 1.47 | |
Operating CF per Share |
0.18 | 0.58 | (0.20) | 0.07 | |
Capex per Share |
(0.03) | (0.04) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.14 | 0.55 | (0.23) | 0.04 | |
Cash per Share |
3.44 | 6.06 | 3.59 | 3.71 | |
Shareholders Equity per Share |
3.77 | 6.27 | 3.97 | 4.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.77 | 6.27 | 3.97 | 4.23 | |
Free Cash Flow |
8.15 | 20.03 | (13.39) | 2.34 | |
Working Capital |
184.78 | 197.21 | 200.75 | 219.43 | |
Capital Expenditures |
(1.99) | (1.35) | (1.56) | (1.66) | |
Net Current Asset Value |
184.78 | 197.21 | 200.75 | 219.43 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 31.70 | 44.93 | |
Average Payables |
— | — | 6.13 | 9.60 | |
Average Inventory |
— | — | 3.56 | 3.79 | |
Average Assets |
143.73 | 152.70 | 151.40 | 315.60 | |
Average Common Equity |
— | — | (75.14) | 233.48 |
Columns are period end dates